Activation of Central PPAR-γ Attenuates Angiotensin II-Induced Hypertension

Hypertension

Volumn 66, Issue 2, 2015, Pages 403-411

  Yu, Yang ^a   Xue, Bao Jian ^b   Wei, Shun Guang ^a   Zhang, Zhi Hua ^a   Beltz, Terry G ^b   Guo, Fang ^b   Johnson, Alan Kim ^b   Felder, Robert B ^a,c  

^a UNIVERSITY OF IOWA   (United States)

^b University of Iowa   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Angiotensin II; Brain; Inflammation; Peroxisome proliferator activated receptors; Renin angiotensin system

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; CYCLOOXYGENASE 2; INTERLEUKIN 1BETA; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; VASOPRESSIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2-CHLORO-5-NITROBENZANILIDE; ANILIDE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; BRAIN TISSUE; CONTROLLED STUDY; DEPRESSOR RESPONSE; DNA BINDING; FLUID INTAKE; FOOD INTAKE; GANGLION BLOCK; HYPERTENSION; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; RAT; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SUBFORNICAL ORGAN; SYMPATHETIC TONE; VASOPRESSIN BLOOD LEVEL; WATER DEPRIVATION; ADRENERGIC SYSTEM; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; BRAIN; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; HEART VENTRICLE REMODELING; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANGIOTENSIN II; ANILIDES; ANIMALS; BLOOD PRESSURE; BRAIN; DISEASE MODELS, ANIMAL; HYPERTENSION; INFUSIONS, INTRAVENTRICULAR; INFUSIONS, SUBCUTANEOUS; MALE; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM; THIAZOLIDINEDIONES; VENTRICULAR REMODELING;

EID: 84937562175     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.05726     Document Type: Article

References (59)

1. Ferrario CM, Strawn WB., Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006;98:121-128. doi: 10.1016/j.amjcard.2006.01.059.
2. Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, Vinh A, Weyand CM., Inflammation, immunity, and hypertension. Hypertension 2011;57:132-140. doi: 10.1161/HYPERTENSIONAHA.110.163576.
3. Xue B, Beltz TG, Yu Y, Guo F, Gomez-Sanchez CE, Hay M, Johnson AK., Central interactions of aldosterone and angiotensin II in aldosterone- and angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol 2011;300:H555-H564. doi: 10.1152/ajpheart.00847.2010.
4. Yu Y, Xue BJ, Zhang ZH, Wei SG, Beltz TG, Guo F, Johnson AK, Felder RB., Early interference with p44/42 mitogen-activated protein kinase signaling in hypothalamic paraventricular nucleus attenuates angiotensin II-induced hypertension. Hypertension 2013;61:842-849. doi: 10.1161/HYPERTENSIONAHA.111.00080
5. Cardinale JP, Sriramula S, Mariappan N, Agarwal D, Francis J., Angiotensin II-induced hypertension is modulated by nuclear factor-κBin the paraventricular nucleus. Hypertension 2012;59:113-121. doi: 10.1161/HYPERTENSIONAHA.111.182154
6. Huang BS, White RA, Bi L, Leenen FH., Central infusion of aliskiren prevents sympathetic hyperactivity and hypertension in Dahl salt-sensitive rats on high salt intake. Am J Physiol Regul Integr Comp Physiol 2012;302:R825-R832. doi: 10.1152/ajpregu.00368.2011
7. Shi P, Diez-Freire C, Jun JY, Qi Y, Katovich MJ, Li Q, Sriramula S, Francis J, Sumners C, Raizada MK., Brain microglial cytokines in neurogenic hypertension. Hypertension 2010;56:297-303. doi: 10.1161/HYPERTENSIONAHA.110.150409
8. Yamazato M, Yamazato Y, Sun C, Diez-Freire C, Raizada MK., Overexpression of angiotensin-converting enzyme 2 in the rostral ventrolateral medulla causes long-term decrease in blood pressure in the spontaneously hypertensive rats. Hypertension 2007;49:926-931. doi: 10.1161/01.HYP.0000259942.38108.20
9. Moore-Carrasco R, Poblete Bustamante M, González Guerra O, Leiva Madariaga E, Mujica Escudero V, Aranguez Arellano C, Palomo I., Peroxisome proliferator-activated receptors: Targets for the treatment of metabolic illnesses (Review). Mol Med Rep 2008;1:317-324.
10. Abbas A, Blandon J, Rude J, Elfar A, Mukherjee D., PPAR- γ agonist in treatment of diabetes: Cardiovascular safety considerations. Cardiovasc Hematol Agents Med Chem 2012;10:124-134.
11. Usuda D, Kanda T., Peroxisome proliferator-activated receptors for hypertension. World J Cardiol 2014;6:744-754. doi: 10.4330/wjc.v6.i8.744
12. Dobrian AD, Schriver SD, Khraibi AA, Prewitt RL., Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Hypertension 2004;43:48-56. doi: 10.1161/01.HYP.0000103629.01745.59
13. Nakamoto M, Ohya Y, Shinzato T, Mano R, Yamazato M, Sakima A, Takishita S., Pioglitazone, a thiazolidinedione derivative, attenuates left ventricular hypertrophy and fibrosis in salt-sensitive hypertension. Hypertens Res 2008;31:353-361. doi: 10.1291/hypres.31.353
14. Dovinová I, Barancik M, Majzunova M, Zorad S, Gajdosechová L, Gresová L, Cacanyiova S, Kristek F, Balis P, Chan JY., Effects of PPAR γ Agonist Pioglitazone on Redox-Sensitive Cellular Signaling in Young Spontaneously Hypertensive Rats. PPAR Res 2013;2013:541871. doi: 10.1155/2013/541871
15. Dorafshar AH, Moodley K, Khoe M, Lyon C, Bryer-Ash M., Pioglitazone improves superoxide dismutase mediated vascular reactivity in the obese Zucker rat. Diab Vasc Dis Res 2010;7:20-27. doi: 10.1177/1479164109341688
16. Schöndorf T, Forst T, Hohberg C, Pahler S, Link C, Roth W, Pfützner A, Lübben G, Link C, Pfützner A., The IRIS III study: Pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight. Diabetes Obes Metab 2007;9:132-133. doi: 10.1111/j.1463-1326.2006.00582.x
17. Derosa G, Fogari E, Cicero AF, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Gravina A, Ferrari I, Fogari R., Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res 2007;30:387-394. doi: 10.1291/hypres.30.387
18. Abe M, Okada K, Kikuchi F, Matsumoto K., Clinical investigation of the effects of pioglitazone on the improvement of insulin resistance and blood pressure in type 2-diabetic patients undergoing hemodialysis. Clin Nephrol 2008;70:220-228.
19. Moreno S, Farioli-Vecchioli S, Cerù MP., Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 2004;123:131-145.
20. Chan SH, Wu CA, Wu KL, Ho YH, Chang AY, Chan JY., Transcriptional upregulation of mitochondrial uncoupling protein 2 protects against oxidative stress-associated neurogenic hypertension. Circ Res 2009;105:886-896. doi: 10.1161/CIRCRESAHA.109.199018
21. Yu Y, Zhang ZH, Wei SG, Weiss RM, Felder RB., Peroxisome proliferator-activated receptor-γ regulates inflammation and renin-angiotensin system activity in the hypothalamic paraventricular nucleus and ameliorates peripheral manifestations of heart failure. Hypertension 2012;59:477-484. doi: 10.1161/HYPERTENSIONAHA.111.182345
22. Glatz T, Stöck I, Nguyen-Ngoc M, Gohlke P, Herdegen T, Culman J, Zhao Y., Peroxisome-proliferator-activated receptors gamma and peroxisome-proliferator-activated receptors beta/delta and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain. J Hypertens 2010;28:1488-1497. doi: 10.1097/HJH.0b013e3283396e4e
23. Morgenweck J, Abdel-Aleem OS, McNamara KC, Donahue RR, Badr MZ, Taylor BK., Activation of peroxisome proliferator-activated receptor gamma in brain inhibits inflammatory pain, dorsal horn expression of Fos, and local edema. Neuropharmacology 2010;58:337-345. doi: 10.1016/j.neuropharm.2009.10.008
24. Chan SH, Chan JY., Angiotensin-generated reactive oxygen species in brain and pathogenesis of cardiovascular diseases. Antioxid Redox Signal 2013;19:1074-1084. doi: 10.1089/ars.2012.4585
25. Burmeister MA, Young CN, Braga VA, Butler SD, Sharma RV, Davisson RL., In vivo bioluminescence imaging reveals redox-regulated activator protein-1 activation in paraventricular nucleus of mice with renovascular hypertension. Hypertension 2011;57:289-297. doi: 10.1161/HYPERTENSIONAHA.110.160564
26. Kang YM, Ma Y, Zheng JP, Elks C, Sriramula S, Yang ZM, Francis J., Brain nuclear factor-κ B activation contributes to neurohumoral excitation in angiotensin II-induced hypertension. Cardiovasc Res 2009;82:503-512. doi: 10.1093/cvr/cvp073
27. Zucker IH, Schultz HD, Patel KP, Wang W, Gao L., Regulation of central angiotensin type 1 receptors and sympathetic outflow in heart failure. Am J Physiol Heart Circ Physiol 2009;297:H1557-H1566. doi: 10.1152/ajpheart.00073.2009
28. Brasier AR, Jamaluddin M, Han Y, Patterson C, Runge MS., Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-κB (NF-κB) transcription factor. Mol Cell Biochem 2000;212:155-169.
29. Siebenlist U, Franzoso G, Brown K., Structure, regulation and function of NF-κ B. Annu Rev Cell Biol 1994;10:405-455. doi: 10.1146/annurev.cb.10.110194.002201
30. Tsatsanis C, Androulidaki A, Venihaki M, Margioris AN., Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol 2006;38:1654-1661. doi: 10.1016/j.biocel.2006.03.021
31. Liu X, Luo D, Zheng M, Hao Y, Hou L, Zhang S., Effect of pioglitazone on insulin resistance in fructose-drinking rats correlates with AGEs/RAGE inhibition and block of NADPH oxidase and NF κ B activation. Eur J Pharmacol 2010;629:153-158. doi: 10.1016/j.ejphar.2009.11.059
32. Chan SH, Wu KL, Kung PS, Chan JY., Oral intake of rosiglitazone promotes a central antihypertensive effect via upregulation of peroxisome proliferator-activated receptor-gamma and alleviation of oxidative stress in rostral ventrolateral medulla of spontaneously hypertensive rats. Hypertension 2010;55:1444-1453. doi: 10.1161/HYPERTENSIONAHA.109.149146
33. Genolet R, Wahli W, Michalik L., PPARs as drug targets to modulate inflammatory responses? Curr Drug Targets Inflamm Allergy 2004;3:361-375.
34. Chinetti G, Fruchart JC, Staels B., Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000;49:497-505.
35. Schiffrin EL., Peroxisome proliferator-activated receptors and cardiovascular remodeling. Am J Physiol Heart Circ Physiol 2005;288:H1037-H1043. doi: 10.1152/ajpheart.00677.2004
36. Guo F, Chen XL, Wang F, Liang X, Sun YX, Wang YJ., Role of angiotensin II type 1 receptor in angiotensin II-induced cytokine production in macrophages. J Interferon Cytokine Res 2011;31:351-361. doi: 10.1089/jir.2010.0073
37. Li XC, Zhuo JL., Nuclear factor-κB as a hormonal intracellular signaling molecule: Focus on angiotensin II-induced cardiovascular and renal injury. Curr Opin Nephrol Hypertens 2008;17:37-43. doi: 10.1097/MNH.0b013e3282f2903c
38. Tham DM, Martin-McNulty B, Wang YX, Wilson DW, Vergona R, Sullivan ME, Dole W, Rutledge JC., Angiotensin II is associated with activation of NF-κB-mediated genes and downregulation of PPARs. Physiol Genomics 2002;11:21-30. doi: 10.1152/physiolgenomics.00062.2002
39. Bernardo A, Minghetti L., PPAR-gamma agonists as regulators of microglial activation and brain inflammation. Curr Pharm Des 2006;12:93-109.
40. Meier CA, Chicheportiche R, Juge-Aubry CE, Dreyer MG, Dayer JM., Regulation of the interleukin-1 receptor antagonist in THP-1 cells by ligands of the peroxisome proliferator-activated receptor gamma. Cytokine 2002;18:320-328.
41. Hao GH, Niu XL, Gao DF, Wei J, Wang NP., Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts. Br J Pharmacol 2008;153:1409-1419. doi: 10.1038/bjp.2008.21
42. Benkirane K, Viel EC, Amiri F, Schiffrin EL., Peroxisome proliferator-activated receptor gamma regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo. Hypertension 2006;47:102-108. doi: 10.1161/01.HYP.0000196728.05488.c3
43. Alexis JD, Wang N, Che W, Lerner-Marmarosh N, Sahni A, Korshunov VA, Zou Y, Ding B, Yan C, Berk BC, Abe J., Bcr kinase activation by angiotensin II inhibits peroxisome-proliferator-activated receptor gamma transcriptional activity in vascular smooth muscle cells. Circ Res 2009;104:69-78. doi: 10.1161/CIRCRESAHA.108.188409
44. Wu KL, Chao YM, Tsay SJ, Chen CH, Chan SH, Dovinova I, Chan JY., Role of nitric oxide synthase uncoupling at rostral ventrolateral medulla in redox-sensitive hypertension associated with metabolic syndrome. Hypertension 2014;64:815-824. doi: 10.1161/HYPERTENSIONAHA.114.03777
45. Kelly AS, Bank AJ., The cardiovascular effects of the thiazolidinediones: A review of the clinical data. J Diabetes Complications 2007;21:326-334. doi: 10.1016/j.jdiacomp.2006.03.006
46. Sarafidis PA, Lasaridis AN., Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect. Am J Hypertens 2006;19:646-653. doi: 10.1016/j.amjhyper.2005.12.017
47. Namikoshi T, Tomita N, Satoh M, Haruna Y, Kobayashi S, Komai N, Sasaki T, Kashihara N., Pioglitazone enhances the antihypertensive and renoprotective effects of candesartan in Zucker obese rats fed a high-protein diet. Hypertens Res 2008;31:745-755. doi: 10.1291/hypres.31.745
48. Kong X, Ma MZ, Qin L, Zhang Y, Li XY, Wang GD, Su Q, Zhang DY., Pioglitazone enhances the blood pressure-lowering effect of losartan via synergistic attenuation of angiotensin II-induced vasoconstriction. J Renin Angiotensin Aldosterone Syst 2014;15:259-270. doi: 10.1177/1470320313489061
49. Saavedra JM., Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders. Clin Sci (Lond) 2012;123:567-590. doi: 10.1042/CS20120078
50. Zanchi A, Maillard M, Jornayvaz FR, Vinciguerra M, Deleaval P, Nussberger J, Burnier M, Pechere-Bertschi A., Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals. Diabetologia 2010;53:1568-1575. doi: 10.1007/s00125-010-1756-2
51. Rizos CV, Elisaf MS, Mikhailidis DP, Liberopoulos EN., How safe is the use of thiazolidinediones in clinical practice? Expert Opin Drug Saf 2009;8:15-32. doi: 10.1517/14740330802597821
52. Wei SG, Yu Y, Zhang ZH, Felder RB., Angiotensin II upregulates hypothalamic AT1 receptor expression in rats via the mitogen-activated protein kinase pathway. Am J Physiol Heart Circ Physiol 2009;296:H1425-H1433. doi: 10.1152/ajpheart.00942.2008
53. Mandrekar-Colucci S, Sauerbeck A, Popovich PG, McTigue DM., PPAR agonists as therapeutics for CNS trauma and neurological diseases. ASN Neuro 2013;5:e00129. doi: 10.1042/AN20130030
54. Thal SC, Heinemann M, Luh C, Pieter D, Werner C, Engelhard K., Pioglitazone reduces secondary brain damage after experimental brain trauma by PPAR-γ-independent mechanisms. J Neurotrauma 2011;28:983-993. doi: 10.1089/neu.2010.1685
55. Sriramula S, Cardinale JP, Lazartigues E, Francis J., ACE2 overexpression in the paraventricular nucleus attenuates angiotensin II-induced hypertension. Cardiovasc Res 2011;92:401-408. doi: 10.1093/cvr/cvr242
56. Young CN, Cao X, Guruju MR, Pierce JP, Morgan DA, Wang G, Iadecola C, Mark AL, Davisson RL., ER stress in the brain subfornical organ mediates angiotensin-dependent hypertension. J Clin Invest 2012;122:3960-3964. doi: 10.1172/JCI64583
57. Lob HE, Schultz D, Marvar PJ, Davisson RL, Harrison DG., Role of the NADPH oxidases in the subfornical organ in angiotensin II-induced hypertension. Hypertension 2013;61:382-387. doi: 10.1161/HYPERTENSIONAHA.111.00546
58. Wei SG, Yu Y, Zhang ZH, Felder RB., Proinflammatory cytokines upregulate sympathoexcitatory mechanisms in the subfornical organ of the rat. Hypertension 2015;65:1126-1133. doi: 10.1161/HYPERTENSIONAHA.114.05112
59. Bernardo A, Minghetti L., Regulation of glial cell functions by PPAR-gamma natural and synthetic agonists. PPAR Res 2008;2008:864140. doi: 10.1155/2008/864140